Kit for Analysing NFKB Translocation by Imaging Flow Cytometry Launched

Merck Millipore, the Life Science division of Merck, have introduced the Amnis® NFKB Translocation kit, which allows researchers to better study the nuclear translocation of NFKB, a transcription factor that plays a central role in regulating key mammalian cell processes, including proliferation, inflammation, immune and stress responses. The new kit uses imaging flow cytometry to obtain statistically significant quantitative assessment of NFKB translocation, as well as visual identification of the translocation at a single-cell level.

The optimised kit, which works with cultured cell lines and whole blood cells, conveniently contains directly-conjugated anti-Human NFKB monoclonal antibody, 7-AAD dye and required buffers. Using the dedicated Nuclear Localisation Wizard in the IDEAS software, NFKB translocation can then be studied and quantified in an objective, statistically robust manner. The kit is designed for use with the Amnis® ImageStream®X Mark II and the Amnis® FlowSight® imaging flow cytometers, systems which combine the quantitative power of flow cytometry with the spatial information provided by microscopy.

"With a central role in many cellular responses and human diseases, NFKB continues to be an attractive target for drug discovery," said Patrick Schneider, PhD, Head of Bioscience. "Availability of the Amnis® imaging flow systems in combination with the new NFKB Translocation kit provides immunology and cell biology researchers an easier, higher throughput way to further explore the mechanisms of action of this important transcription factor and reveal insights into targeting its signalling pathway for therapeutic purposes."